The recent academic research on biomarkers for aging prevention highlights several significant findings in 2024. Key studies include the validation of aging biomarkers like the PRC2 complex, which plays a crucial role in longevity interventions, and the exploration of late-life protein or isoleucine restriction impacting physiological aging signatures. Challenges in translating aging biomarkers into clinical practice are also addressed, emphasizing the need for robust validation methods. Other research investigates the effects of senolytic compounds on DNA methylation clocks and the identification of soluble markers like sCD163 and sCD80 for detecting immunosenescence. Together, these studies underscore the potential of leveraging biomarkers to not only understand aging processes but also develop targeted interventions for enhancing human longevity.